Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Kathy Cheung"'
Autor:
J. Porter Hunt, Samuel Dubinsky, Autumn M. McKnite, Kit Wun Kathy Cheung, Bianca D. vanGroen, Kathleen M. Giacomini, Saskia N. deWildt, Andrea N. Edginton, Kevin M. Watt
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 576-588 (2024)
Abstract Optimal treatment of infants with many renally cleared drugs must account for maturational differences in renal transporter (RT) activity. Pediatric physiologically‐based pharmacokinetic (PBPK) models may incorporate RT activity, but this
Externí odkaz:
https://doaj.org/article/7ff55455941a418ca3f7d873a040d3c9
Autor:
Kit Wun Kathy Cheung, Yang Tang, Doreen Anders, Teresa Barata, Astrid Scalori, Priya Agarwal, Rucha Sane, Sravanthi Cheeti
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 564 (2024)
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely
Externí odkaz:
https://doaj.org/article/36e760d984da4103856adc19adf5013b
Autor:
Marianne Uguen, Magalie Hilton, Mufiza Farid-Kapadia, Asim Datye, Saibah Chohan, Claudia Carlucci, Mark Dixon, Markus Elze, Yingjia Chen, Kit Wun Kathy Cheung, Rucha Sane, Maoxia Zheng, YounJeong Choi
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::940c7805da481a9cc3fb88ef0305e553
https://doi.org/10.1080/10543406.2022.2162071
https://doi.org/10.1080/10543406.2022.2162071
Autor:
Sook Wah Yee, Adrian Stecula, Huan-Chieh Chien, Ling Zou, Elena V Feofanova, Marjolein van Borselen, Kit Wun Kathy Cheung, Noha A Yousri, Karsten Suhre, Jason M Kinchen, Eric Boerwinkle, Roshanak Irannejad, Bing Yu, Kathleen M Giacomini
Publikováno v:
PLoS Genetics, Vol 15, Iss 9, p e1008208 (2019)
Variation in steroid hormone levels has wide implications for health and disease. The genes encoding the proteins involved in steroid disposition represent key determinants of interindividual variation in steroid levels and ultimately, their effects.
Externí odkaz:
https://doaj.org/article/5623312d5ce545b0ae5d208f5ebfc7e6
Autor:
Bianca M. Liederer, Susan Wong, Vikram Malhi, Kit Wun Kathy Cheung, Justin Hanover, Luna Musib, Eunpi Cho, Rucha Sane, Emile Plise
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 378:87-95
Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug interaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05aadd54e04339b8c2243bae5816ccf2
https://doi.org/10.1124/jpet.121.000620
https://doi.org/10.1124/jpet.121.000620
Autor:
Jing Jing, Yuan Chen, Luna Musib, Jin Y. Jin, Kit Wun Kathy Cheung, Kenta Yoshida, Rucha Sane
Publikováno v:
Cancer chemotherapy and pharmacology. 89(5)
Purpose Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a substrate and a time-dependent inhibitor of CYP3A4. It exhibits non-linear pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c5684b47094345756d8fc3969d2d9f3
https://pubmed.ncbi.nlm.nih.gov/35428895
https://pubmed.ncbi.nlm.nih.gov/35428895
Autor:
Buyun Chen, Roland Morley, Kenta Yoshida, Kit Wun Kathy Cheung, Lichuan Liu, Iris T Chan, Sravanthi Cheeti, Srikumar Sahasranaman
Publikováno v:
Drug Metabolism and Disposition. 47:966-973
GDC-0810 (Cheeti et al., 2018) is an orally bioavailable, selective estrogen receptor (ER) degrader developed to treat ER-positive breast cancer. A first-in-human (FIH) dose escalation phase I study (n = 41) was conducted to characterize the pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::402261aa975f59481f6e620526e8cc35
https://doi.org/10.1124/dmd.119.087924
https://doi.org/10.1124/dmd.119.087924
Autor:
Howard Lee, Yoshikazu Hayashi, Delese Mimi Darko, Dan Hartman, Ling Zou, Elizabeth A. E. Green, Steven E. Kern, Kit Wun Kathy Cheung, Lawrence Lin, Terrence F. Blaschke, Paul A. Akpa, Emer Cooke, Murray Lumpkin, Jennifer L. Wilson, Carl C. Peck, Russ B. Altman, Sheng Ding, Peter W. Marks, Analía Porrás, David Mukanga, Wiltshire C. N. Johnson, Kathleen M. Giacomini, Rae Yuan
Publikováno v:
Science translational medicine, vol 12, iss 554
Sci Transl Med
Sci Transl Med
Requiring regional or in-country confirmatory clinical trials before approval of drugs already approved elsewhere delays access to medicines in low- and middle-income countries and raises drug costs. Here, we discuss the scientific and technological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16e2569e6fc18b7d1d6fc3ba9f102e6
https://escholarship.org/uc/item/3rr8c18v
https://escholarship.org/uc/item/3rr8c18v
Autor:
Zsuzsanna Gáborik, Emile Plise, Luna Musib, Emese Kis, Taleah Farasyn, Rucha Sane, Kit Wun Kathy Cheung, Annamaria Bui, Peter Kovacs, Ruina Li
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 48(12)
Organic anion-transporting polypeptide (OATP) 1B1/3-mediated drug-drug interaction (DDI) potential is evaluated in vivo with rosuvastatin (RST) as a probe substrate in clinical studies. We calibrated our assay with RST and estradiol 17-β-D-glucuroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c34af0b13cd9f825b56bf72765490e0d
https://pubmed.ncbi.nlm.nih.gov/33037044
https://pubmed.ncbi.nlm.nih.gov/33037044
Autor:
Nicholas Choong, Yuzhong Deng, Ilsung Chang, Sandhya Girish, Luna Musib, Ian Templeton, Sravanthi Cheeti, Kit Wun Kathy Cheung, Isabela Georgescu
Publikováno v:
Clinical Pharmacology in Drug Development
Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09689ac191d1cd71733df0ecf52f48ef
https://pubmed.ncbi.nlm.nih.gov/32696585
https://pubmed.ncbi.nlm.nih.gov/32696585